CORELATION OF ROMA ALGORITHM TO PATHOLOGICAL CHARACTERISTICS AND THE STAGES OF DISEASE IN OVARIAN CANCER

2016 ◽  
pp. 48-56
Author(s):  
Huy Hoang Dang ◽  
Cong Thuan Dang
Keyword(s):  
Ovarian Cancer ◽  
Tumor Size ◽  
Histological Grade ◽  
Female Reproductive Tract ◽  
Disease Stage ◽  
Serous Carcinoma ◽  
Sensitivity Index ◽  
Key Words Ovarian Cancer ◽  
Stage Of Disease ◽  
Pathological Characteristics

Ovarian cancer is highly mortality in the gynecological cancers, accounting for 15-20% cancers of the female reproductive tract. Patients with primary ovarian cancer have often detected at later stages. Risk of Ovarian Malignancy Algorithm (ROMA) is used for the purpose of assessing the risk of malignancy for choosing appropriate treatments in ovarian tumors. Howerver, the objective of this study was to examine the correlation of ROMA index with pathological characteristics and the stage of disease in patients with ovarian cancer. The crossing describes study conducted in 34 patients with ovarian cancer at Hue Central Hospital during 31 months. Results showed that average age of ovarian cancer was 51.32 ± 12.51; 64.7% of cases were postmenopausal. Tumor size common was 5-10cm (50%). Ovarian serous carcinoma is the highest percentage (55.9%). Ovarian cancer is often detected at stage III (64.7%) according to the TNM and FIGO classification. The average concentration of CA125 and HE4 increases with stage of disease. ROMA had a sensitivity index higher among postmenopausal patients (95%). We conclude that ROMA index significantly correlated with stages of disease according to the FIGO (r=0,358; p<0,05) and TNM (r=0,345; p<0,05) classification, inversely correlated with histological grades and no correlation with tumor size in ovarian cancer. Key words: ovarian cancer, ROMA, histological grade, disease stage

scholarly journals Comparison of clinico-pathological characteristics and survival of recurrent ovarian cancer patients on seven different chemo-protocols

2019 ◽  
Vol 69 (1) ◽  
pp. 87-97
Author(s):  
Saima Sattar ◽  
Mobasher Ahmad ◽  
Hamid Saeed ◽  
Zikria Saleem ◽  
Zeeshan Danish ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Histological Grade ◽  
Progression Free Survival ◽  
Complete Response ◽  
Recurrent Ovarian Cancer ◽  
Figo Stage ◽  
Care Hospital ◽  
Pathological Characteristics ◽  
Literature Evidence

Abstract Despite growing prevalence of ovarian cancer (OC) in Pakistan, no literature evidence exists regarding its clinic-pathological characteristics, survival and compliance of patients with recurrent ovarian cancer on various chemo-protocols. An observational study was conducted by enrolling 251 recurrent OC patients on 7 different chemo-protocols, from a specialized cancer care hospital, Lahore, Pakistan, using convenient judgmental sampling. The study was conducted for a period of 6 months. Most of the patients were between 18 and 70 years of age, with IIIC FIGO stage and papillary serous histological grade. As per RECIST, improved partial response (PR) (63.3 %) and complete response (CR) (52.1 %) was observed in the CP (carboplatin + paclitaxel) arm, substantiated by improved median progression free survival (PFS) and overall survival (OS) in CP and CD (carboplatin + docetaxel) arms, respectively, yet with no significant differences in survival curves, PFS (p = 0.12) and OS (p = 0.22). Interestingly, the highest and the lowest patient non-compliance were observed in CG (carboplatin + gemcitabine) (81.6 %) and paclitaxel (4.5 %) arms, resp. As per the hazard model for survival, topotecan showed significant association with the therapy related events/deaths compared to other protocols. These data suggest that CP regimen exhibited improved clinical efficacy and decreased toxicity related non-compliance in recurrent ovarian cancer patients of Lahore.

STUDY ON RELATION BETWEEN TRADITIONAL PROGNOSIS FACTORS AND HORMONE RECEPTORS STATUS, KI-67, HER2 IN INVASIVE BREAST CARCINOMA

2017 ◽  
pp. 70-76
Author(s):  
Cong Thuan Dang ◽  
Thi Thu Thuy Phan ◽  
Nam Dong Tran ◽  
Cao Sach Ngo ◽  
Thi Hong Van Vo
Keyword(s):  
Lymph Node ◽  
Breast Carcinoma ◽  
Lymph Node Metastasis ◽  
Tumor Size ◽  
Hormone Receptors ◽  
Histological Grade ◽  
Invasive Breast Carcinoma ◽  
Disease Stage ◽  
Ki 67 ◽  
Node Metastasis

Objectives: To examine histopathologic features and hormone receptors status, Ki-67 and HER2 in invasive breast carcinoma at Hue University Hospital to evaluating the relation between tumor size, histological grade, lymph node metastasis status, disease stage and the expression of steroid hormone receptors status, Ki-67 and HER2 in invasive breast carcinoma. Materials and methods: From May 2015 to April 2016, samples were collected from 96 breast carcinoma patients. Histopathologic samples were stained by Hematoxylin-Eosin and immunohistochemistry staining at Pathology Department, Hue University Hospital. R esults: Most invasive breast carcinoma patients were among the age of 50-59 (39.6%), invasive ductal carcinoma (82.3%), tumor size ≤2cm (54.2%), histological grade II (60.2%), lymph node metastasis (53.1%), disease stage II (51%); ER(+) 46.9%, PR(+) 49.0%, Ki-67(+) 77.1%, HER2(+) 30.2% of cases. Conclusion: There were a positive correlation between histological grade with the HER2 expression (p<0.05) in invasive breast carcinoma. Key words: invasive breast carcinoma, immunohistochemistry, tumor size, histological grade, lymph node metastasis, disease stage

Fallopian tubes and ovarian cancer (Literature review)

2019 ◽  
pp. 92-95
Author(s):  
D.G. Sumtsov ◽  
◽  
M.L. Kusyomenska ◽  
G.A. Sumtsov ◽  
◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Literature Review ◽  
Preventive Measures ◽  
Disease Incidence ◽  
Molecular Genetic ◽  
Serous Ovarian Cancer ◽  
Fallopian Tubes ◽  
Key Words Ovarian Cancer ◽  
Pelvic Peritoneum ◽  
Opportunistic Salpingectomy

In the literature review the authors present an analysis of the current stateproblem of ovarian cancer and ways of its possible solution. According to clinicalobservations and conducted in recent decades by morphological,immunohistochemical and molecular genetic studies it is fairly proved that theprimary cause of serous ovarian cancer is the pathology of the mucous layer offallopian tube. In the fallopian tube as a result of ciculation of inflammation andcarcinogens elements arises dysplasia of the mucosa with the development of thepreinvasive and initial invasive carcinoma with subsequent damage of the ovariesand pelvic peritoneum. Retrospective studies of a significant number of women’shealth status who had a deligation or removal of fallopian tubes in previous years showed a decrease in the disease incidence of serous ovarian cancer from 30 to 90%. The conclusions about the possibility of preventive measures of ovariancancer by opportunistic salpingectomy at post-productive age are made. In many world countries (Canada, China, France, Italy, Austria) the introduction of such a method of prevention has been started. We believe that in Ukraine there is an urgent need and all possibilities to solve this problem. Key words: ovarian cancer, preventive measures, opportunistic salpingectomy.

CLINICAL SIGNIFICANCE OF SERUM CAVEOLIN-1 LEVELS IN GASTRIC CANCER PATIENTS

2018 ◽  
Vol 40 (4) ◽  
pp. 323-327 ◽  
Author(s):  
F Tas ◽  
S Karabulut ◽  
K Erturk ◽  
D Duranyildiz
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Histological Grade ◽  
Clinical Importance ◽  
Disease Stage ◽  
Control Group ◽  
Tissue Samples ◽  
Caveolin 1 ◽  
Study Results ◽  
Gastric Cancer Patients

Aim: Caveolin-1 plays a significant role in the pathogenesis of various carcinomas and its expression affects the survival of cancer patients. However, the molecular function of caveolin-1 and its possible clinical importance has remained uncertain in gastric cancer. No clinical trial has examined serum caveolin-1 levels in gastric cancer patients so far, instead all available results were provided from studies conducted on tissue samples. In the current study, we analyzed the soluble serum caveolin-1 levels in gastric cancer patients, and specified its associations with the clinical factors and prognosis. Material and Methods: Sixty-three patients with pathologically confirmed gastric cancer were enrolled into the trial. Serum caveolin-1 concentrations were detected by ELISA method. Thirty healthy subjects were also included in the study. Results: The median age of patients was 62 years, ranging from 28 to 82 years. The serum caveolin-1 levels in gastric cancer patients were significantly higher than those in control group (p < 0.001). The common clinical parameters including patient age, sex, lesion localization, histopathology, histological grade, disease stage, and various serum tumor markers (e.g. LDH, CEA, and CA 19.9) were not found to be associated with serum caveolin-1 levels (p > 0.05). Similarly, no correlation existed between serum caveolin-1 concentration and chemotherapy responsiveness (p = 0.93). Furthermore, serum caveolin-1 level was not found to have a prognostic role (p = 0.16). Conclusion: Even though it is neither predictive nor prognostic, serum caveolin-1 level may be a valuable diagnostic indicator in patients with gastric cancer. Key

scholarly journals Targeting progesterone signaling prevents metastatic ovarian cancer

2020 ◽  
Vol 117 (50) ◽  
pp. 31993-32004
Author(s):  
Olga Kim ◽  
Eun Young Park ◽  
Sun Young Kwon ◽  
Sojin Shin ◽  
Robert E. Emerson ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Deleterious Mutation ◽  
Peritoneal Metastases ◽  
Cancer Development ◽  
Serous Carcinoma ◽  
Cancer Type ◽  
High Grade ◽  
Primary Tumors ◽  
High Risk Populations ◽  
Genetic Deletion

Effective cancer prevention requires the discovery and intervention of a factor critical to cancer development. Here we show that ovarian progesterone is a crucial endogenous factor inducing the development of primary tumors progressing to metastatic ovarian cancer in a mouse model of high-grade serous carcinoma (HGSC), the most common and deadliest ovarian cancer type. Blocking progesterone signaling by the pharmacologic inhibitor mifepristone or by genetic deletion of the progesterone receptor (PR) effectively suppressed HGSC development and its peritoneal metastases. Strikingly, mifepristone treatment profoundly improved mouse survival (∼18 human years). Hence, targeting progesterone/PR signaling could offer an effective chemopreventive strategy, particularly in high-risk populations of women carrying a deleterious mutation in the BRCA gene.

scholarly journals Clinical significance of circulating tumor cell related markers in patients with epithelial ovarian cancer before and after adjuvant chemotherapy

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Meysam Yousefi ◽  
Sara Rajaie ◽  
Vahideh Keyvani ◽  
Somayeh Bolandi ◽  
Malihe Hasanzadeh ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Adjuvant Chemotherapy ◽  
Epithelial Ovarian Cancer ◽  
Clinical Significance ◽  
Therapy Response ◽  
Serum Levels ◽  
Circulating Tumor Cell ◽  
Tumor Stage ◽  
Disease Stage ◽  
Before And After

AbstractCirculating tumor cells (CTCs) have recently been considered as new prognostic and diagnostic markers for various human cancers; however, their significance in epithelial ovarian cancer (EOC) remains to be elucidated. In this study, using quantitative real-time PCR, we evaluated the expression of EPCAM, MUC1, CEA, HE4 and CA125 mRNAs, as putative markers of CTCs, in the blood of 51 EOC patients before and/or after adjuvant chemotherapy. Our results demonstrated that, before chemotherapy, the expression of EPCAM, MUC1, CEA and HE4 mRNAs were correlated to each other. CEA expression was correlated with tumor stage (r = 0.594, p = 0.000) before chemotherapy, whereas its expression after chemotherapy was correlated with serum levels of CA125 antigen (r = 0.658, p = 0.000). HE4 mRNA showed the highest sensitivity both before and after chemotherapy (82.98% and 85.19%, respectively) and the persistence of this marker after chemotherapy was associated with advanced disease stage. The expression of CA125 mRNA had negative correlation with the other markers and with tumor stage and therapy response (evaluated by the measurement of serum CA125 antigen). Collectively, our results indicated a better clinical significance of tumor-specific markers (CEA and HE4 mRNAs) compared to epithelial-specific markers (EPCAM and MUC1 mRNAs).

scholarly journals Tumour Versus Germline BRCA Testing in Ovarian Cancer: A Single-Site Institution Experience in the United Kingdom

Diagnostics ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. 547
Author(s):  
Iolia Akaev ◽  
Siavash Rahimi ◽  
Olubukola Onifade ◽  
Francis John Edward Gardner ◽  
David Castells-Rufas ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Unknown Origin ◽  
Parp Inhibitors ◽  
Serous Carcinoma ◽  
High Grade ◽  
Brca1 And Brca2 ◽  
Brca Mutations ◽  
Epithelial Cancers ◽  
Pathogenic Variants ◽  
Pathogenic Mutations

The aim of this audit was to evaluate the usefulness and serviceability of testing for pathogenic mutations in BRCA1 or BRCA2 (BRCA1/2) genes in ovarian cancer (OC) patients. One hundred and thirty-five patients with more common histological sub-types of OC were retrospectively identified between 2011 and 2019. The fail rate of the molecular analysis was 7.4% (10/135). One hundred and twenty-five records were evaluated: 99 (79.2%) patients had wild-type BRCA (both somatic and germline); tumour BRCA1/2 (tBRCA1/2) pathogenic mutations were found in 20 (16%) patients with distribution between BRCA1 and BRCA2 being 40% and 60%, respectively; 13 (10.4%) patients with pathogenic variants had germline mutations; and tBRCA1/2 with variant of unknown significance (VUS), in the absence of pathogenic BRCA1 or BRCA2 variants, was detected in 6 (4.8%) patients. Our data show that expanding the molecular service to the routine first-tumour testing for patients with OC will potentially increase the detection rate of BRCA mutations, thereby providing early benefits of PARP inhibitors therapy. The tumour testing service should continue to be offered to newly diagnosed patients with high-grade epithelial cancers, including high-grade serous carcinoma, but also with carcinosarcomas and poorly-differentiated metastatic adenocarcinomas of unknown origin.

scholarly journals Low-grade serous epithelial ovarian cancer: a comprehensive review and update for radiologists

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Sofia Amante ◽  
Filipa Santos ◽  
Teresa Margarida Cunha
Keyword(s):  
Ovarian Cancer ◽  
Serous Carcinoma ◽  
Low Grade ◽  
Resonance Imaging ◽  
Clinicopathologic Characteristics ◽  
Borderline Tumour ◽  
Molecular Features ◽  
Serous Epithelial Ovarian Cancer ◽  
The Difference

AbstractLow-grade serous carcinoma (LGSC) is an infrequent subtype of ovarian cancer, corresponding to 5% of epithelial neoplasms. This subtype of ovarian carcinoma characteristically has molecular features, pathogenesis, clinical behaviour, sensitivity to chemotherapy, and prognosis distinct to high-grade serous carcinoma (HGSC). Knowing the difference between LGSC and other ovarian serous tumours is vital to guide clinical management, which currently is only possible histologically. However, imaging can provide several clues that allow differentiating LGSC from other tumours and enable precise staging and follow-up of ovarian cancer treatment. Characteristically, LGSC appears as mixed lesions with variable papillary projections and solid components, usually in different proportions from those detected in serous borderline tumour and HGSC. Calcified extracellular bodies, known as psammoma bodies, are also a common feature of LGSC, frequently detectable within lymphadenopathies and metastases associated with this type of tumour. In addition, the characterisation of magnetic resonance imaging enhancement also plays an essential role in calculating the probability of malignancy of these lesions. As such, in this review, we discuss and update the distinct radiological modalities features and the clinicopathologic characteristics of LGSC to allow radiologists to be familiarised with them and to narrow the differential diagnosis when facing this type of tumour.

The expression of programmed death-ligand 1 and its association with histopathological grade, stage of disease, and occurrence of metastasis in breast cancer

2021 ◽  
pp. 1-6
Author(s):  
Agung Sindu Pranoto ◽  
Haryasena Haryasena ◽  
Prihantono Prihantono ◽  
Septiman Rahman ◽  
Daniel Sampepajung ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cross Sectional Study ◽  
Disease Stage ◽  
Tumor Escape ◽  
Cross Sectional ◽  
Programmed Death Ligand 1 ◽  
Histopathological Grade ◽  
Stage Of Disease ◽  
Programmed Death ◽  
The Relationship

INTRODUCTION: Programmed death ligand 1 (PD-L1) plays a role in tumor escape and progression by inactivating T lymphocytes. The aim of the study reported here was to determine the relationship between the expression of PD-L1 and histopathological grade, stage of disease, and the occurrence of metastasis in breast cancer. METHODS: The observational cross-sectional study involved analyzing the expression of PD-L1 by immunohistochemistry. RESULTS: PD-LI was expressed in 43 of 60 patients with breast cancer (71.6%), mostly with a moderate histopathological grade (58.3%) and at an advanced stage (50%). Associations between the expression of PD-L1 and histopathological grade (p = 0.011), stage of disease (p = 0.009), and the occurrence of metastasis (p = 0.01) were significant, with an odds ratio of 5. CONCLUSION: The associations between the expression of PD-L1 and histopathological grade, disease stage, and occurrence of metastasis were all significant in cases of breast cancer in the sample. Those findings suggest that the expression of PD-L1 increases the progression of breast cancer.

Stem-like tumor cells and proinflammatory cytokines in the ascitic fluid of ovarian cancer patients

2021 ◽  
Vol 66 (5) ◽  
pp. 297-303
Author(s):  
S. O. Gening ◽  
T. V. Abakumova ◽  
I. I. Antoneeva ◽  
A. A. Rizvanov ◽  
T. P. Gening ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Blood Serum ◽  
Tumor Cells ◽  
Ascitic Fluid ◽  
Early Stage ◽  
Abdominal Cavity ◽  
Disease Stage ◽  
Cell Populations ◽  
Benign Ovarian Tumors ◽  
Number Of Cells

Ovarian cancer (OC) is able to develop implantation metastases in the abdominal cavity. Ascites is potentially useful for evaluating cancer features. The aim of the study was to assess the content of stem-like tumor cells and inflammatory mediators in ascites of OC. The prospective study included 11 patients with primary OC having ascites, 8 patients with benign ovarian tumors having ascites and 22 healthy women. In ascitic fluid obtained by laparocentesis, the populations of tumor stem-like cells were determined on a Cytoflex S` flow cytometer (Beckman Coulter, USA) and CytExpert Software using monoclonal antibodies to CD45, CD44 and CD133. The cytokine profiles of ascitic fluid and blood serum (IL-1β, IL-18, IL-4, IL-10 and VEGF) were assessed by ELISA. Stem-like cells were found in all samples. 5 cell populations were evaluated. The number of cells expressing both markers: CD44 + and CD133+, was the lowest. The highest, about 32%, was the number of CD44+ cells. The number of cells CD45-CD44+CD133- in ascites strongly positively correlated with the content of IL-10 in ascites, and the numbers of CD45-CD133+ and CD45-CD44-CD133+ - with the level of VEGF in blood serum. No correlations were found between the numbers of stem-like cells and the disease stage or the level of CA125 in blood. The combination of IL-4 and IL-10 in ascites had the greatest significance in predicting the disease stage. These results suggest a relationship between the levels of VEGF, IL-10, and cancer stem cells in the OC ascites. Stem-like cells in OC ascites are heterogeneous and are present even at an early stage of the disease. It seems promising to study cell populations and cytokine profile of ascites together, to assess the biomarker potential of their combination.

Sign in / Sign up

Export Citation Format

Share Document